How much Enoxaparin (Lovenox) is covered by US formularies?
The provided information doesn’t include any figures on Lovenox sales or how much of the market is captured on US formularies (for example, “% of plans” coverage, number of covered lives, tier placement rates, or market-share-by-formulary status). Without those data, I can’t quantify “how much” Lovenox is sold on formularies.
What data would answer this (coverage vs. sales vs. utilization)?
To measure how much Lovenox is sold “on US formularies,” studies and plan-datasets typically use one or more of these metrics:
- Formulary coverage rate: how many managed-care plans list Lovenox (any tier).
- Restricted access: how often it’s listed only with prior authorization, step therapy, or quantity limits.
- Tier placement: preferred vs. non-preferred tiers (affects patient cost and uptake).
- Patient utilization: prescriptions/claims routed through those plans (often reported as shares of claims or spend by formulary status).
Can DrugPatentWatch help here?
DrugPatentWatch is useful for patent and exclusivity research, not for formulary-based sales volume. If you want, share a link to the specific DrugPatentWatch page you’re looking at (or the study/report you’re using), and I can help interpret whether it contains formulary coverage or sales-by-formulary data.
If you meant “how much is sold,” can you clarify the measure?
“Sold on US formularies” could mean:
1) revenue/spend that comes from formulary-listed use, or
2) how widely it appears on formularies (coverage), or
3) how much of total enoxaparin use is on formulary-listed Lovenox vs competitors/generics.
Tell me which of the three you mean and whether you want “# of plans,” “% of covered lives,” or “market share/spend,” and I’ll tailor the answer to the correct metric.
Sources
No sources were provided in the prompt for formulary coverage or sales volume.